Atrial Fibrillation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment, By End-use, By Region & Competition), 2021-2031F

Description

The Global Atrial Fibrillation Market is poised for significant growth, projected to expand from USD 22.61 Billion in 2025 to USD 35.34 Billion by 2031, achieving a CAGR of 7.73%. This market encompasses various medical devices and pharmaceutical treatments for diagnosing, managing, and treating irregular cardiac rhythms, including electrophysiology ablation catheters, diagnostic mapping systems, and left atrial appendage closure devices. Key growth drivers include an expanding geriatric population and the increasing global prevalence of chronic conditions like hypertension and obesity, which elevate arrhythmia risk. For instance, in 2025, the UK recorded 1.62 million atrial fibrillation diagnoses, highlighting the growing clinical need. However, a major impediment to market expansion is the high cost of advanced electrophysiology procedures and ongoing disease management, leading to stringent reimbursement policies and restricted patient access, particularly in cost-sensitive healthcare systems and emerging markets.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 22.61 Billion
Market Size 2031	USD 35.34 Billion
CAGR 2026-2031	7.73%
Fastest Growing Segment	Hospital
Largest Market	North America

Market Driver

The market is significantly driven by the advent of Pulsed Field Ablation (PFA) systems, which offer a safer and more efficient non-thermal alternative to traditional ablation techniques. PFA's ability to selectively ablate myocardial tissue while protecting surrounding structures has led to reduced procedural times and rapid adoption by electrophysiologists for various atrial fibrillation cases. Boston Scientific's Farapulse PFA system, for example, generated $1 billion in revenue within its first year, demonstrating this technological shift. Furthermore, the rising prevalence of cardiovascular comorbidities, such as hypertension and obesity, greatly expands the patient population needing interventions. With approximately 127.9 million U.S. adults affected by some form of cardiovascular disease in 2025, the demand for scalable atrial fibrillation management solutions is intensifying, leading to strong growth for manufacturers, as evidenced by Johnson & Johnson's cardiology division's 22.3% growth in Q2 2025.

Market Challenge

A significant impediment to the Global Atrial Fibrillation Market's expansion is the considerable cost of advanced electrophysiology procedures and ongoing disease management. Procedures like catheter ablation and left atrial appendage closure demand substantial investment in specialized equipment and infrastructure, leading healthcare payers to impose strict reimbursement policies that limit patient access. This financial barrier often slows the adoption of new medical technologies, particularly in cost-sensitive healthcare systems and emerging economies. The economic strain is compounded by the long-term expenses of chronic care, including lifelong anticoagulation and continuous monitoring. With the annual cost of managing atrial fibrillation in the UK estimated to surpass £2.4 billion in 2025, this fiscal burden drives restrictive purchasing policies that hinder overall market development.

Market Trends

Two key trends are shaping the atrial fibrillation market: the growing utilization of Left Atrial Appendage Closure Devices and the development of Next-Generation Factor XIa Inhibitors. Clinicians are increasingly adopting Left Atrial Appendage Closure Devices for non-pharmacological stroke prevention, particularly for high-risk patients prone to bleeding complications, moving away from long-term oral anticoagulation. This shift has led manufacturers to innovate with safer, more effective devices, accelerating adoption, as seen in Boston Scientific's Watchman franchise, which grew by 28.4% in Q2 2025. Concurrently, Next-Generation Factor XIa Inhibitors are emerging as a transformative pharmaceutical trend. These novel therapeutics promise to enhance stroke prophylaxis by preventing clot formation without impairing natural hemostasis, thereby significantly reducing major bleeding events-a critical safety concern with existing anticoagulants. For instance, the Factor XI inhibitor abelacimab demonstrated a 62% reduction in bleeding events compared to rivaroxaban, indicating its substantial clinical potential.

Key Market Players

Parexel International Corporation
AtriCure Inc.
Boehringer Ingelheim GmbH
Boston Scientific Corporation
Bristol- Myers Squibb Corporation
Cardio Focus Inc.
Sanofi S.A.
Biosense Webster Inc.
Endoscopic Technologies Inc.
Abbott Laboratories
Johnsons & Johnson Services, Inc.

Report Scope

In this report, the Global Atrial Fibrillation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atrial Fibrillation Market, By Treatment Type

Pharmacological Treatment
Non-Pharmacological Treatment

Atrial Fibrillation Market, By End-use

Hospital
Specialty Clinics
Others

Atrial Fibrillation Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Atrial Fibrillation Market.

Available Customizations:

Global Atrial Fibrillation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atrial Fibrillation Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Treatment Type (Pharmacological Treatment (Anti-arrhythmic Drugs), Non-Pharmacological Treatment(Catheter Ablation, Maze Surgery, Electric Cardioversion))
- 5.2.2. By End-use (Hospital, Specialty Clinics, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Atrial Fibrillation Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Treatment Type
- 6.2.2. By End-use
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Atrial Fibrillation Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Treatment Type
    - 6.3.1.2.2. By End-use
- 6.3.2. Canada Atrial Fibrillation Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Treatment Type
    - 6.3.2.2.2. By End-use
- 6.3.3. Mexico Atrial Fibrillation Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Treatment Type
    - 6.3.3.2.2. By End-use

7. Europe Atrial Fibrillation Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Treatment Type
- 7.2.2. By End-use
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Atrial Fibrillation Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Treatment Type
    - 7.3.1.2.2. By End-use
- 7.3.2. France Atrial Fibrillation Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Treatment Type
    - 7.3.2.2.2. By End-use
- 7.3.3. United Kingdom Atrial Fibrillation Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Treatment Type
    - 7.3.3.2.2. By End-use
- 7.3.4. Italy Atrial Fibrillation Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Treatment Type
    - 7.3.4.2.2. By End-use
- 7.3.5. Spain Atrial Fibrillation Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Treatment Type
    - 7.3.5.2.2. By End-use

8. Asia Pacific Atrial Fibrillation Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Treatment Type
- 8.2.2. By End-use
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Atrial Fibrillation Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Treatment Type
    - 8.3.1.2.2. By End-use
- 8.3.2. India Atrial Fibrillation Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Treatment Type
    - 8.3.2.2.2. By End-use
- 8.3.3. Japan Atrial Fibrillation Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Treatment Type
    - 8.3.3.2.2. By End-use
- 8.3.4. South Korea Atrial Fibrillation Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Treatment Type
    - 8.3.4.2.2. By End-use
- 8.3.5. Australia Atrial Fibrillation Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Treatment Type
    - 8.3.5.2.2. By End-use

9. Middle East & Africa Atrial Fibrillation Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Treatment Type
- 9.2.2. By End-use
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Atrial Fibrillation Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Treatment Type
    - 9.3.1.2.2. By End-use
- 9.3.2. UAE Atrial Fibrillation Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Treatment Type
    - 9.3.2.2.2. By End-use
- 9.3.3. South Africa Atrial Fibrillation Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Treatment Type
    - 9.3.3.2.2. By End-use

10. South America Atrial Fibrillation Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Treatment Type
- 10.2.2. By End-use
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Atrial Fibrillation Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Treatment Type
    - 10.3.1.2.2. By End-use
- 10.3.2. Colombia Atrial Fibrillation Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Treatment Type
    - 10.3.2.2.2. By End-use
- 10.3.3. Argentina Atrial Fibrillation Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Treatment Type
    - 10.3.3.2.2. By End-use

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Atrial Fibrillation Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Parexel International Corporation
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. AtriCure Inc.
15.3. Boehringer Ingelheim GmbH
15.4. Boston Scientific Corporation
15.5. Bristol- Myers Squibb Corporation
15.6. Cardio Focus Inc.
15.7. Sanofi S.A.
15.8. Biosense Webster Inc.
15.9. Endoscopic Technologies Inc.
15.10. Abbott Laboratories
15.11. Johnsons & Johnson Services, Inc.